CJC-1295/Ipamorelin Blend (5/5 mg)
$59.99
Dual growth hormone secretagogue blend for endocrine research
Overview [research use only]
The CJC-1295/Ipamorelin Blend combines two well-studied peptides that act synergistically on growth hormone pathways. CJC-1295 (a modified GHRH analogue) stimulates pulsatile release of growth hormone, while Ipamorelin (a selective ghrelin receptor agonist) enhances this effect without significantly impacting cortisol, prolactin, or ACTH levels. Together, they provide a potent and selective model for investigating growth hormone dynamics, tissue repair, metabolism, and age-related endocrine decline in preclinical research.
Specifications
- Synonyms: CJC-1295 + Ipamorelin, Modified GRF (1-29) + Ipamorelin
- Composition: CJC-1295 (5 mg) + Ipamorelin (5 mg)
- Molecular formulas:
â CJC-1295: C152H252N44O42 (~3367.9 g/mol)
â Ipamorelin: C38H49N9O5 (~711.9 g/mol)
- CAS numbers:
â CJC-1295: 863288-34-0
â Ipamorelin: 170851-70-4
- Appearance: White to off-white lyophilized (freeze-dried) powder
 Packaging and Storage
Supplied as a lyophilized powder blend in vials (5 mg CJC-1295 and 5 mg Ipamorelin). Store at â20 °C for long-term preservation, protected from light and moisture. After reconstitution with sterile water or buffer, aliquot and store at 2â8 °C for short-term use or â20 °C for extended stability. Avoid repeated freezeâthaw cycles.
Safety and Legal
For laboratory research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.
| Weight | .5 lbs |
|---|---|
| Dimensions | .63 × .63 × 1.4 in |
Related products
MK-677: Ibutamoren (25 mg/mL, 50 mL)
In stock
Semaglutide (5 mg, 10 mg)
In stock
Tirzepatide (5 mg, 10 mg)
In stock
